文献速递肝病消化道肿瘤与早癌

用靶向磷脂酰肌醇蛋白聚糖3的HLA-A2限制性鼠源T细胞受体工程化的人T细胞可在小鼠体内有效控制人肝细胞癌

Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice.
PubMed 文献 · Hepatology · 2024-11-26

研究用表达人GPC3的腺病毒免疫HLA-A2转基因小鼠,鉴定出识别GPC3(522-530)表位的鼠源TCR,并构建TCR-T细胞。TCR-B-T细胞在体外和异种移植肝癌模型中表现出优于二代41BB GPC3 CAR-T细胞的效应功能、增殖能力和疗效,且与CAR-T混合给药较序贯给药更有效。

要点

  • 从HLA-A2转基因小鼠中鉴定出3个识别GPC3(522-530)表位的鼠源TCR。
  • TCR-B-T细胞在异种移植模型中疗效优于二代41BB GPC3 CAR-T细胞。
  • CAR-T与TCR-B-T混合给药较同种细胞序贯给药显著更有效。

核心结论

  • 转基因TCR与CAR联合可扩展靶向GPC3的肝细胞癌T细胞治疗受体库。

研究设计与样本

  • 用表达人GPC3的腺病毒免疫HLA-A2转基因小鼠,鉴定识别GPC3(522-530)表位的TCR。
  • 克隆3个鼠源GPC3-TCR(TCR-A、TCR-B、TCR-C)并工程化原代人T细胞。
  • 在体外及异种移植肝细胞癌模型中评价TCR-T细胞的功能与疗效。

主要发现

  • TCR-T细胞有效识别GPC3阳性HLA-A2阳性人肝细胞癌细胞,GPC3沉默和HLA-A2阻断可减弱该识别。
  • TCR-B-T和TCR-C-T细胞反应性最高,TCR-B-T细胞效应功能、增殖能力和异种移植模型疗效最优。
  • TCR-B-T细胞优于二代41BB GPC3 CAR-T细胞,归因于耗竭更低、增殖增强、效应功能更强和耐受性更好。
  • CAR-T与TCR-B-T混合给药显著优于同种细胞序贯给药,提示潜在协同效应。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Glypican-3 (GPC3) is a promising target for T-cell therapy in HCC. While chimeric antigen receptor (CAR) T cells targeting GPC3 have demonstrated therapeutic efficacy, their effectiveness is limited by challenges such as low persistence and shedding of surface GPC3. Natural T-cell receptors (TCRs) may serve as an alternative, though identifying GPC3-specific TCRs within the endogenous repertoire is difficult. APPROACH AND RESULTS: We immunized human leucocyte antigen-A2 (HLA-A2) transgenic mice with an adenovirus expressing human GPC3, identifying a panel of TCRs that recognize the GPC3(522-530) epitope. We cloned 3 murine GPC3-TCRs (TCR-A, TCR-B, and TCR-C) and engineered primary human T cells (TCR-T). TCR-T cells effectively recognized GPC3 + HLA-A2 + human HCC cells, with recognition diminished by GPC3 silencing and HLA-A2 blockade. TCR-B-T and TCR-C-T cells showed the highest reactivity, with TCR-B-T cells exhibiting superior effector functions, proliferative capacity, and therapeutic efficacy in xenograft HCC models. Notable, TCR-B-T cells outperformed second-generation 41BB GPC3-specific CAR-T cells, attributed to lower exhaustion, enhanced proliferation, greater effector function, and improved resilience. Furthermore, mixed dosing of CAR-T and TCR-B-T cells was significantly more effective than staggered dosing of the same cell type, suggesting potential synergistic effects. CONCLUSIONS: Transgenic TCRs join forces with CARs, expanding the arsenal of GPC3-targeting receptors for HCC T-cell therapy.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Vercher E, Covo-Vergara Á, Conde E, et al. Human T cells engineered with an HLA-A2-restricted murine T-cell receptor targeting glypican 3 effectively control human hepatocellular carcinoma in mice. Hepatology. 2024. PMID: 39601444. doi:10.1097/HEP.0000000000001175

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。